Nutrient Synergy
Ivonescimab Meets Overall Survival Goal in NSCLC
By emily johnson · 275
Nutrient Synergy
Ivonescimab Meets Overall Survival Goal in NSCLC
By emily johnson · 290
Nutrient Synergy
Ivonescimab Meets Overall Survival Goal in NSCLC
By emily johnson · 276
Nutrient Synergy
Ivonescimab Meets Overall Survival Goal in NSCLC
By emily johnson · 317 Views · September 7, 2026
Microbiome Diversity 
Microbiome Diversity 
Ivonescimab Meets Overall Survival Goal in NSCLC
0 by emily johnson
Ivonescimab Meets Overall Survival Goal in NSCLC
0 by emily johnson
Ivonescimab Meets Overall Survival Goal in NSCLC
0 by emily johnson
Ivonescimab Meets Overall Survival Goal in NSCLC
0 by emily johnson
Ivonescimab Meets Overall Survival Goal in NSCLC
0 by emily johnson
Ivonescimab Meets Overall Survival Goal in NSCLC
0 by emily johnson
Recovery Modalities
HiRO and Differentia Biotech collaborate on trial simulation
HiRO and Differentia Biotech collaborate on advanced clinical trial simulation models. Learn how this AI-driven partnership aims to...
August 31, 2026
Recovery Modalities
Daiichi Sankyo Begins Phase I DS1025 Trial
First patient dosing has begun in the Phase I DS1025 study , a trial that will assess an...
August 29, 2026
Editor's picks
Why Is Medicaid Member Engagement Essential for Health
Medicaid is a cornerstone of healthcare access for millions of Americans, including low-income families, seniors, and individuals with disabilities. While...
August 27, 2026
ESC 2026 AstraZeneca oral relaxin passes Phase II
AstraZeneca's AZD5462 shows promise in Phase II trial for chronic heart failure, improving cardiac function via relaxin pathway.
September 2, 2026
ESC 2026 AstraZeneca oral relaxin passes Phase II
By Samoyed · Sep 2, 2026
Why Is Medicaid Member Engagement Essential for Health
By Samoyed · Aug 27, 2026
All Post
Nutrient Synergy
Ivonescimab Meets Overall Survival Goal in NSCLC
Ivonescimab surpasses Keytruda in overall survival for NSCLC first-line treatment, demonstrating potential breakthrough in lung cancer therapy.
emily johnson 135 Views September 7, 2026
Nutrient Synergy
Ivonescimab Meets Overall Survival Goal in NSCLC
Ivonescimab surpasses Keytruda in overall survival for NSCLC first-line treatment, demonstrating potential breakthrough in lung cancer therapy.
emily johnson 265 Views September 7, 2026
Nutrient Synergy
Ivonescimab Meets Overall Survival Goal in NSCLC
Ivonescimab surpasses Keytruda in overall survival for NSCLC first-line treatment, demonstrating potential breakthrough in lung cancer therapy.
emily johnson 156 Views September 7, 2026
Nutrient Synergy
Ivonescimab Meets Overall Survival Goal in NSCLC
Ivonescimab surpasses Keytruda in overall survival for NSCLC first-line treatment, demonstrating potential breakthrough in lung cancer therapy.
emily johnson 232 Views September 7, 2026
Nutrient Synergy
Ivonescimab Meets Overall Survival Goal in NSCLC
Ivonescimab surpasses Keytruda in overall survival for NSCLC first-line treatment, demonstrating potential breakthrough in lung cancer therapy.
emily johnson 99 Views September 7, 2026
Nutrient Synergy
Ivonescimab Meets Overall Survival Goal in NSCLC
Ivonescimab surpasses Keytruda in overall survival for NSCLC first-line treatment, demonstrating potential breakthrough in lung cancer therapy.
emily johnson 126 Views September 7, 2026
Nutrient Synergy
Ivonescimab Meets Overall Survival Goal in NSCLC
Ivonescimab surpasses Keytruda in overall survival for NSCLC first-line treatment, demonstrating potential breakthrough in lung cancer therapy.
emily johnson 246 Views September 7, 2026
Recovery Modalities
Sensorion gets green light for HearConnex trial
Sensorion's HearConnex trial gets green light for hearing loss treatment with gene therapy SENS-601.
Samoyed 137 Views September 4, 2026
Nutrient Synergy
Alumis lupus drug advances after trial setback
Alumis advances its lupus drug to Phase III trials despite mixed Phase IIb results, targeting a specific patient subgroup for better outcomes.
Samoyed 171 Views September 3, 2026
Somatic Drills
ESC 2026 AstraZeneca oral relaxin passes Phase II
AstraZeneca's AZD5462 shows promise in Phase II trial for chronic heart failure, improving cardiac function via relaxin pathway.
Samoyed 277 Views September 2, 2026